Clinical-stage T-cell immunotherapy company developing TCR-T therapies for hard-to-treat cancers.
| Date | Round | Amount |
|---|---|---|
| Aug 2025 | Funding round Anocca raised $46 million led by Mellby Gard to bring VIDAR-1 into the clinic, a TCR-T therapy targeting mutant KRAS in pancreatic cancer. | $46M |
| Dec 2022 | Debt Sweden-based cell therapy biotech Anocca raised EUR25M in venture debt from the European Investment Bank under InvestEU to advance its T-cell immunotherapies. | $27M |
| Aug 2021 | Series B Swedish biotech Anocca raised a USD 47M Series B from Swedbank Robur Ny Teknik, Ramsbury Invest and others to advance its T-cell therapies. | $47M |